Skip to main content

Table 1 Comparison of demographic, clinical, laboratory and therapeutic data between the two follow-up groups

From: Medium-term chest computed tomography (CT) follow-up of COVID-19 pneumonia patients after recovery to assess the rate of resolution and determine the potential predictors of persistent lung changes

Parameter Complete radiological resolution on follow-up CT (n = 46; 56.8%) Residual lung findings on follow-up CT (n = 35; 43.2%) p value
Age (Mean ± SD) 45.8 ± 13.8 59.6 ± 9.3 0.01858
Sex M = 29 (63%)
F = 17 (37%)
M = 21 (60%)
F = 14 (40%)
0.8205
BMI
  18–25 34 (74%) 14 (40%) 0.003
  > 25 12 (26%) 21 (60%)  
Smoking history
  Smoker 13 (28.3%) 18 (51.4%) 0.6497
  Non-smoker 33 (71.7%) 17 (48.6%)  
Comorbidity
  Absent 26 (56.5%) 7 (20%)  
  Present 20 (43.5%) 28 (80%)  
  Diabetes mellitus 6 8  
  Hypertension 7 7  
  COPD 4 5 0.0013
  CKD 1 2  
  CLD 1 2  
  CAD 1 1  
  Malignancy 0 2  
  Immune suppression 0 1  
Hospitalization
  Inpatient 34 (74%) 31 (88.6%) 0.1583
  Outpatient 12 (26%) 4 (11.4%)  
In-ward hospitalization 43 (93.5%) 25 (71.4%) 0.0126
ICU admission 3 (6.5%) 10 (28.6%)  
Duration of hospitalization
  (Mean days ± SD) 7.6 ± 2.3 11.2 ± 4.1 0.000332
Initial percutaneous oxygen saturation (%)
  (Mean ± SD) 92.3 ± 3.8 88.1 ± 2.2 0.00132
Initial WBC count
  ×103 (Mean ± SD) 5343 ± 1456.4 7987 ± 2465.8 0.00105
NLR 2.5 ± 1.1 2.8 ± 1.3 0.609
LDH, IU/l
  (Mean ± SD) 697.7 ± 198.8 743.8 ± 211.4 0.6921
CRP, mg/l
  (Mean ± SD) 34.6 ± 17.6 41.1 ± 19.8 0.4554
Pharmacological treatment
  Antiviral drugs 16 (34.8%) 13 (37.1%) 1
  Hydroxychloroquine 12 (26%) 17 (48.6%) 0.63
  Steroids 39 (84.8%) 18 (51.4%) 0.0007
Persistent symptoms on follow-up 30 (65.2%) 24 (68.5%) 0.8148
  1. CT computed tomography, BMI body mass index, NLR neutrophil to lymphocyte ratio, CRP C-reactive protein, LDH lactate dehydrogenase, WBC white blood cell count, COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, CLD chronic liver disease, CAD coronary artery disease